Previous 10 | Next 10 |
Cogent Biosciences (NASDAQ:COGT) stock rose ~5% premarket June 10 after the company reported initial data from an ongoing phase 2 trial of bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). Systemic Mastocytosis is a rare disorder in which a type of white blood cell c...
All patients treated with bezuclastinib achieved ≥ 50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment All bone marrow biopsy-assessed patients achieved ≥ 50% bone marrow mast cell reduction...
CAMBRIDGE, Mass. and BOULDER, Colo., June 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it will host an investor webcast on Friday, June 10, 2022 a...
CAMBRIDGE, Mass. and BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the Annual Meeting of Stockholders will take place virtuall...
CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced a poster presentation at the European Hematology Association...
Cogent Biosciences press release (NASDAQ:COGT): Q1 Net loss was $30.6 million. As of March 31, 2022, cash and cash equivalents were $191.0 million as compared to $219.7 million as of December 31, 2021. For further details see: Cogent Biosciences reports Q1 results
Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a portfolio of discovery stage programs, creating potential best-in-class small molecule kinase inhibitors for genetically defined oncology indications and ...
Cogent Biosciences (NASDAQ:COGT) on Friday filed for a $300M mixed shelf offering. The offering can include stock, preferred stock, debt securities, warrants and units. Proceeds will be used for development, regulatory and commercial preparation activities relating to bezuclastinib and other ...
CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in a fireside chat at the L...
Shares of Cogent Biosciences Inc. (NASDAQ:COGT) traded at a new 52-week high today of $13.82. Approximately 17.1 million shares have changed hands today, as compared to an average 30-day volume of 250,000 shares. Over the past year, Cogent Biosciences Inc. has traded in a range of $2.20 ...
News, Short Squeeze, Breakout and More Instantly...
Cogent Biosciences Inc Com Company Name:
COGT Stock Symbol:
NASDAQ Market:
Cogent Biosciences Inc Com Website:
2024-07-06 14:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
WALTHAM, Mass. and BOULDER, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has reached alignment with the U.S. Food and Drug Admin...
2024-06-26 16:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...